1384193-00-3

Basic information

• Product Name: (4S)-4-benzyl-3-[(3R,4E)-3-hydroxy-5-phenylpent-4-enoyl]-1,3-thiazolidine-2-thione
• Synonyms: (4S)-4-benzyl-3-[(3R,4E)-3-hydroxy-5-phenylpent-4-enoyl]-1,3-thiazolidine-2-thione
• CAS NO: 1384193-00-3
• Molecular Weight: 383.535
• Mol File: 1384193-00-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (4S)-4-benzyl-3-[(3R,4E)-3-hydroxy-5-phenylpent-4-enoyl]-1,3-thiazolidine-2-thione(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-benzyl-3-[(3R,4E)-3-hydroxy-5-phenylpent-4-enoyl]-1,3-thiazolidine-2-thione(1384193-00-3)
• EPA Substance Registry System: (4S)-4-benzyl-3-[(3R,4E)-3-hydroxy-5-phenylpent-4-enoyl]-1,3-thiazolidine-2-thione(1384193-00-3)

Safety Data

• Hazardous Substances Data: 1384193-00-3(Hazardous Substances Data)

Upstream product

• 123-73-9 crotonaldehyde 
• 790661-41-5 (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)ethan-1-one 
• 14371-10-9 (E)-3-phenylpropenal 

Downstream Products

• 866324-09-6 (3R,5R,6E)-3,5-bis{[tert-butyl(dimethyl)silyl]oxy}-7-phenylhept-6-enal 
• 678970-54-2 (2E,8E)-(5S,7R)-5,7-Bis-(tert-butyl-dimethyl-silanyloxy)-9-phenyl-nona-2,8-dienal 
• 678970-59-7 (R)-6-[(1E,4S,6R,7E)-4,6-bis{[tert-butyl(dimethyl)silyl]oxy}-8-phenylocta-1,7-dien-1-yl]-5,6-dihydro-2H-pyran-2-one 
• 917251-11-7 (3R,4E)-3-(tert-butyldimethylsilanyloxy)-5-phenylpent-4-enal 
• 1384193-02-5 (R)-4-benzyl-3-[(3R,5R,6E)-3,5-bis{[tert-butyl(dimethyl)silyl]oxy}-7-phenylhept-6-enoyl]-1,3-thiazolidine-2-thione 
• 1384193-03-6 (4R,6S,8R,9E)-6,8-bis{[tert-butyl(dimethyl)silyl]oxy}-10-phenyldeca-1,9-dien-4-ol 
• 1384193-04-7 (1R,3S,5R,6E)-1-allyl-3,5-bis{[tert-butyl(dimethyl)silyl]oxy}-7-phenylhept-6-en-1-yl acrylate 
• 1384192-98-6 (R)-6-[(2S,4R,5E)-2,4-bis{[tert-butyl(dimethyl)silyl]oxy}-6-phenylhex-5-en-1-yl]-5,6-dihydro-2H-pyran-2-one 
• 1384193-05-8 (2E,5S,7R,8E)-5,7-bis{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N-methyl-9-phenylnona-2,8-dienamide 
• 1384192-99-7 (R)-4-benzyl-3-[(3R,5R,6E)-5-{[tert-butyl(dimethyl)silyl]oxy}-3-hydroxy-7-phenylhept-6-enoyl]-1,3-thiazolidine-2-thione 
• 1384193-08-1 (R)-4-benzyl-3-[(3S,5R,6E)-5-{[tert-butyl(dimethyl)silyl]oxy}-3-hydroxy-7-phenylhept-6-enoyl]-1,3-thiazolidine-2-thione 
• 1384193-01-4 (S)-4-benzyl-3-[(3R,4E)-3-{[tert-butyl(dimethyl)silyl]oxy}-5-phenylpent-4-enoyl]-1,3-thiazolidine-2-thione 
• 1260145-38-7 (1E,3R,5S)-1-phenylocta-1,7-diene-3,5-diol 
• 1260145-21-8 (4S,6R)-4-allyl-2,2-dimethyl-6-[(E)-2-phenylvinyl]-1,3-dioxane 

Relevant articles and documents

Synthesis of the Proposed Structure of Cryptoconcatone H

A synthesis of the proposed structure of cryptoconcatone H and one diastereoisomer has been achieved, featuring a tandem deprotection-oxa-Michael addition to establish the tetrahydropyran moiety. Comparison of the NMR spectroscopic data confirms that the original structural assignment was incorrect.

Anti-trypanosome anticancer natural product Cryptofolione synthesizing method

The invention discloses an anti-trypanosome anticancer natural product Cryptofolione synthesizing method. The synthesizing method disclosed by the invention comprises the steps: after acrolein and silyl enol ether are utilized to perform Mukaiyama aldol reaction, sodium borohydride is used for reducing ketone into alcohol, and then pyridinium p-toluenesulfonate refluxes in a methylbenzene solutionto obtain compound shown in a formula 5; after cinnamyl aldehyde and an evans chiral aid are used for performing evans aldol reaction, diisobutyl aluminum hydride is used for reducing the cinnamyl aldehyde and the evans chiral aid at first, and then addition with metal indium activated 3-propylene bromine is performed to obtain compound shown in a formula 9; the compound shown in the formula 9 isresolved and purified for many times by kinetic resolution; the compound shown in the formula 9 and 2,2-diemthoxy propane can obtain fragment type 10 compound under the pyridinium p-toluenesulfonatecondition, the fragment type 10 compound and fragment type 5 compound can generate olefin metathesis reaction through a Grubbs secondary catalyst, and protecting groups of the fragment type 10 compound are removed under the hydrochloric acid condition to obtain Cryptofolione.

Stereoselective Total Synthesis of Cryptomoscatone F1

A concise stereoselective total synthesis of cryptomoscatone F1 has been accomplished by utilization of asymmetric acetate aldol reaction, Brown's asymmetric allylation, and olefin cross-metathesis as key transformations.